

# I MÃ¡rquez-Rodas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3581490/publications.pdf>

Version: 2024-02-01

128  
papers

20,524  
citations

147801

31  
h-index

31849

101  
g-index

131  
all docs

131  
docs citations

131  
times ranked

22876  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	27.0	6,773
2	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	27.0	3,589
3	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546.	27.0	2,484
4	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	27.0	1,752
5	Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1480-1492.	10.7	1,089
6	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 863-873.	10.7	561
7	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 226-235.	1.6	458
8	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	1.6	446
9	Adjuvant nivolumab versus ipilimumab in resected stage IIIbâ€“C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1465-1477.	10.7	330
10	Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. <i>Nature</i> , 2019, 569, 428-432.	27.8	313
11	Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 867-875.	1.6	258
12	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774974.	3.2	200
13	ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1435-1448.	1.2	132
14	Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2017, 3, 1511.	7.1	131
15	Participation of Prostacyclin in Endothelial Dysfunction Induced by Aldosterone in Normotensive and Hypertensive Rats. <i>Hypertension</i> , 2005, 46, 107-112.	2.7	115
16	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. <i>Clinical Cancer Research</i> , 2017, 23, 649-657.	7.0	108
17	Immunotherapeutic effects of intratumoral nanoplexed poly I:C. , 2019, 7, 116.		91
18	Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. <i>Clinical Cancer Research</i> , 2018, 24, 1845-1852.	7.0	84

#	ARTICLE	IF	CITATIONS
19	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. <i>Clinical Cancer Research</i> , 2018, 24, 5820-5829.	7.0	82
20	Supervised physical exercise improves VO2max, quality of life, and health in early stage breast cancer patients: a randomized controlled trial. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 371-382.	2.5	73
21	Deregulated miRNAs in Hereditary Breast Cancer Revealed a Role for miR-30c in Regulating KRAS Oncogene. <i>PLoS ONE</i> , 2012, 7, e38847.	2.5	71
22	ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. <i>Annals of Oncology</i> , 2020, 31, 1449-1461.	1.2	69
23	Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial. <i>Annals of Oncology</i> , 2019, 30, v533-v534.	1.2	65
24	Who detects melanoma? Impact of detection patterns on characteristics and prognosis of patients with melanoma. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 967-974.	1.2	61
25	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 119, 168-178.	2.8	61
26	Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1 refractory tumors. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	51
27	CCL20 Expression by Tumor-Associated Macrophages Predicts Progression of Human Primary Cutaneous Melanoma. <i>Cancer Immunology Research</i> , 2018, 6, 267-275.	3.4	49
28	Running away from side effects: physical exercise as a complementary intervention for breast cancer patients. <i>Clinical and Translational Oncology</i> , 2015, 17, 180-196.	2.4	47
29	Immune checkpoint inhibitors: therapeutic advances in melanoma. <i>Annals of Translational Medicine</i> , 2015, 3, 267.	1.7	47
30	MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors. <i>International Journal of Cancer</i> , 2015, 136, 593-602.	5.1	43
31	Circulating Tumor Cells Following First Chemotherapy Cycle: An Early and Strong Predictor of Outcome in Patients With Metastatic Breast Cancer. <i>Oncologist</i> , 2013, 18, 917-923.	3.7	41
32	Pathophysiology and therapeutic possibilities of calcitonin gene-related peptide in hypertension. <i>Journal of Physiology and Biochemistry</i> , 2006, 62, 45-56.	3.0	38
33	Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9522-9522.	1.6	37
34	The RANK-RANKL axis: an opportunity for drug repurposing in cancer?. <i>Clinical and Translational Oncology</i> , 2019, 21, 977-991.	2.4	31
35	The NER-related gene <i>GTF2H5</i> predicts survival in high-grade serous ovarian cancer patients. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e7.	2.2	30
36	Aldosterone modulates neural vasomotor response in hypertension: role of calcitonin gene-related peptide. <i>Regulatory Peptides</i> , 2004, 120, 253-260.	1.9	28

#	ARTICLE	IF	CITATIONS
37	Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. <i>Breast Cancer Research and Treatment</i> , 2016, 156, 507-515.	2.5	27
38	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 121, 144-153.	2.8	27
39	Neratinib (HKI-272) in the treatment of breast cancer. <i>Future Oncology</i> , 2012, 8, 671-681.	2.4	26
40	Predictive factors of response to immunotherapy—a review from the Spanish Melanoma Group (GEM). <i>Annals of Translational Medicine</i> , 2017, 5, 389-389.	1.7	26
41	Neurogenic nitric oxide release increases in mesenteric arteries from ouabain hypertensive rats. <i>Journal of Hypertension</i> , 2004, 22, 949-957.	0.5	25
42	MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours. <i>British Journal of Cancer</i> , 2013, 109, 2724-2734.	6.4	23
43	Neratinib for the treatment of HER2-positive early stage breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 669-679.	2.4	22
44	Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 1375-1383.	3.7	22
45	SEOM clinical guideline for the management of cutaneous melanoma (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 948-960.	2.4	22
46	LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004. <i>Annals of Oncology</i> , 2020, 31, S1173.	1.2	21
47	Long-term fenofibrate treatment impairs endothelium-dependent dilation to acetylcholine by altering the cyclooxygenase pathway. <i>Cardiovascular Research</i> , 2007, 75, 398-407.	3.8	20
48	Protein kinase A increases electrical stimulation-induced neuronal nitric oxide release in rat mesenteric artery. <i>European Journal of Pharmacology</i> , 2004, 487, 167-173.	3.5	18
49	Aldosterone increases RAMP1 expression in mesenteric arteries from spontaneously hypertensive rats. <i>Regulatory Peptides</i> , 2006, 134, 61-66.	1.9	18
50	Deletion at 6q24.2â€“26 predicts longer survival of highâ€“grade serous epithelial ovarian cancer patients. <i>Molecular Oncology</i> , 2015, 9, 422-436.	4.6	17
51	SEOM clinical guideline for the management of malignant melanoma (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 69-74.	2.4	16
52	Cirrhosis decreases vasoconstrictor response to electrical field stimulation in rat mesenteric artery: role of calcitonin gene-related peptide. <i>Experimental Physiology</i> , 2011, 96, 275-286.	2.0	15
53	Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients. <i>Clinical and Translational Oncology</i> , 2020, 22, 555-562.	2.4	14
54	The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study. <i>Melanoma Research</i> , 2018, 28, 333-340.	1.2	13

#	ARTICLE	IF	CITATIONS
55	Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts. <i>Scientific Reports</i> , 2021, 11, 7064.	3.3	13
56	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	4.4	12
57	Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program. <i>Clinical and Translational Oncology</i> , 2017, 19, 761-768.	2.4	12
58	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12
59	Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 181-189.	2.5	11
60	Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). , 2021, 9, e001664.		11
61	Cambios epidemiolÃ³gicos en el melanoma cutÃ¡neo: estudio retrospectivo de 969 casos (1996-2010). <i>Revista Clinica Espanola</i> , 2013, 213, 81-87.	0.6	10
62	Melanoma proteomics suggests functional differences related to mutational status. <i>Scientific Reports</i> , 2019, 9, 7217.	3.3	10
63	Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. <i>Drugs</i> , 2020, 80, 131-146.	10.9	10
64	Primary ovarian Burkitt lymphoma. <i>Clinical and Translational Oncology</i> , 2008, 10, 673-675.	2.4	9
65	A new era in the treatment of melanoma: from biology to clinical practice. <i>Clinical and Translational Oncology</i> , 2011, 13, 787-792.	2.4	9
66	Treatment patterns of adjuvant interferon-Î±2b for high-risk melanoma: a retrospective study of the Grupo EspaÃ±ol Multidisciplinar de Melanoma â€œ Prima study. <i>Melanoma Research</i> , 2016, 26, 278-283.	1.2	8
67	Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511). <i>Annals of Oncology</i> , 2018, 29, viii737.	1.2	8
68	Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors. <i>Annals of Oncology</i> , 2018, 29, viii732.	1.2	8
69	1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone. <i>Annals of Oncology</i> , 2020, 31, S734-S735.	1.2	8
70	CCL20/TNF/VEGFA Cytokine Secretory Phenotype of Tumor-Associated Macrophages Is a Negative Prognostic Factor in Cutaneous Melanoma. <i>Cancers</i> , 2021, 13, 3943.	3.7	8
71	Frequency and Characteristics of Familial Melanoma in Spain: The FAM-GEM-1 Study. <i>PLoS ONE</i> , 2015, 10, e0124239.	2.5	8
72	Increased expression in calcitonin-like receptor induced by aldosterone in cerebral arteries from spontaneously hypertensive rats does not correlate with functional role of CGRP receptor. <i>Regulatory Peptides</i> , 2008, 146, 125-130.	1.9	7

#	ARTICLE	IF	CITATIONS
73	Family History Record and Hereditary Cancer Risk Perception according to National Cancer Institute Criteria in a Spanish Medical Oncology Service: A Retrospective Study. <i>Oncology</i> , 2012, 82, 30-34.	1.9	7
74	Review: circulating tumor cells in the practice of breast cancer oncology. <i>Clinical and Translational Oncology</i> , 2016, 18, 749-759.	2.4	7
75	Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. <i>Future Oncology</i> , 2017, 13, 2137-2149.	2.4	7
76	Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-16.	3.0	7
77	Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience. <i>Clinical and Translational Oncology</i> , 2020, 22, 717-724.	2.4	7
78	10760 Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238. <i>Annals of Oncology</i> , 2020, 31, S731-S732.	1.2	7
79	Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis. <i>JMIR Cancer</i> , 2022, 8, e35930.	2.4	7
80	Dabrafenib plus trametinib for compassionate use in metastatic melanoma. <i>Medicine (United States)</i> , 2017, 96, e9523.	1.0	6
81	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238). <i>Annals of Oncology</i> , 2017, 28, v632-v633.	1.2	6
82	Utility of PET/CT in patients with stage III melanoma. <i>Clinical and Translational Oncology</i> , 2020, 22, 1414-1417.	2.4	6
83	An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9584-9584.	1.6	6
84	Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit. <i>Journal of Genetic Counseling</i> , 2018, 27, 854-862.	1.6	5
85	COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1412-1415.	1.2	5
86	EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600 mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF/MEK inhibition.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9540-9540.	1.6	5
87	Exclusion Criteria vs Reality: Dual BRAF/MEK Inhibition and Radiotherapy in a Patient with Melanoma Metastatic to the Brain and ECOG 3. <i>Tumori</i> , 2016, 102, S54-S56.	1.1	4
88	For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity. <i>Clinical Cancer Research</i> , 2019, 25, 1127-1129.	7.0	4
89	LBA66_PR Disparities in access to oncology clinical trials in Europe in the period 2009-2019. <i>Annals of Oncology</i> , 2020, 31, S1196.	1.2	4
90	Evaluation of a Heredofamilial Cancer Unit in Increasing Family History Collection and Genetic Counseling Referrals Among Spanish Oncologists at a University Hospital. <i>Journal of Genetic Counseling</i> , 2014, 23, 108-113.	1.6	3

#	ARTICLE	IF	CITATIONS
91	Cost-Effectiveness of Ipilimumab for Previously Untreated Patients with Advanced Metastatic Melanoma in Spain. <i>Value in Health</i> , 2014, 17, A631.	0.3	3
92	Cyclin Kinase Inhibitors in Breast Cancer: From Bench to Bedside. <i>Current Breast Cancer Reports</i> , 2014, 6, 79-87.	1.0	3
93	Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067). <i>Annals of Oncology</i> , 2018, 29, viii735.	1.2	3
94	1038MO Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial. <i>Annals of Oncology</i> , 2021, 32, S870.	1.2	3
95	Why do patients with thick melanoma have different outcomes? A retrospective epidemiological and survival analysis. <i>Clinical and Translational Oncology</i> , 2017, 19, 1055-1057.	2.4	2
96	Five Years of Multidisciplinary Care in Hereditary Cancer: Our Experience in a Spanish University Hospital. <i>Oncology</i> , 2017, 92, 68-74.	1.9	2
97	Safety and immunobiological activity of intratumoral (IT) double-stranded RNA (dsRNA) BO-112 in solid malignancies: First in human clinical trial. <i>Annals of Oncology</i> , 2017, 28, v612.	1.2	2
98	Combination of intratumoural double-stranded RNA (dsRNA) BO-112 with systemic anti-PD-1 in patients with anti-PD-1 refractory cancer. <i>Annals of Oncology</i> , 2019, 30, xi37-xi38.	1.2	2
99	Metastatic melanoma with spontaneous regression, psoriasis and HLA-Cw6: case report and a hypothesis to explore. <i>Tumori</i> , 2014, 100, 144e-7e.	1.1	2
100	Melanoma de uretra masculina: caso clÃnico. <i>Actas UrolÃ³gicas EspaÃ±olas</i> , 2010, 34, 651-652.	0.7	1
101	3540 POSTER Perception of Hereditary Cancer Risk in a Medical Oncology Service: a Retrospective Study. <i>European Journal of Cancer</i> , 2011, 47, S258.	2.8	1
102	A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain. <i>Clinical and Translational Oncology</i> , 2019, 21, 1754-1762.	2.4	1
103	Abstract CT233: Phase 2 clinical study to evaluate the efficacy and safety of intratumoral BO-112 in combination with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapy. <i>Cancer Research</i> , 2021, 81, CT233-CT233.	0.9	1
104	Venous thromboembolism incidence in cancer patients with germline BRCA mutations. <i>Clinical and Translational Oncology</i> , 2021, , 1.	2.4	1
105	1056P Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study. <i>Annals of Oncology</i> , 2021, 32, S881-S882.	1.2	1
106	Utilidad de la tomografÃa por emisiÃ³n de positrones en el diagnÃstico del nÃdulo pulmonar solitario con alta probabilidad de malignidad. <i>Revista De Patologia Respiratoria</i> , 2009, 12, 69-73.	0.0	0
107	Melanoma of male urethra: A clinical case. <i>Actas UrolÃ³gicas EspaÃ±olas (English Edition)</i> , 2010, 34, 651-652.	0.2	0
108	619 Deciphering Non-BRCA1/2 Familial Breast Tumor Heterogeneity by MiRNA Expression Profiling. <i>European Journal of Cancer</i> , 2012, 48, S147.	2.8	0

#	ARTICLE	IF	CITATIONS
109	The Implementation of a Multidisciplinary Heredofamilial Cancer Unit Changes Hereditary Cancer Risk Perception among Oncologists. <i>Annals of Oncology</i> , 2012, 23, ix176-ix177.	1.2	0
110	A Multidisciplinary Approach to Heredofamilial Cancer Syndromes: Evaluation of the First Four Years of Experience at a Spanish University Hospital. <i>Annals of Oncology</i> , 2014, 25, iv166.	1.2	0
111	Evaluation of breast cancer patients with genetic risk: Before and after a multidisciplinary heredofamilial cancer unit implementation. <i>Annals of Oncology</i> , 2016, 27, vi465.	1.2	0
112	Intrinsic subtype and response to neoadjuvant chemotherapy with carboplatin and docetaxel (TCb) in triple-negative breast cancer (TNBC). <i>Annals of Oncology</i> , 2016, 27, vi56.	1.2	0
113	GRAY-B: An open label multicenter phase-2 GEM study on ipilimumab and radiation in patients with melanoma and brain metastases. <i>Annals of Oncology</i> , 2016, 27, vi383.	1.2	0
114	Burden of Healthcare Costs for Merkel Cell Carcinoma Management in Spain. <i>Value in Health</i> , 2017, 20, A427.	0.3	0
115	Validation of the Royal Marsden Hospital (RMH) prognostic score on an enriched early treatment line cohort for phase I trial patients. <i>Annals of Oncology</i> , 2017, 28, v135.	1.2	0
116	Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). <i>Annals of Translational Medicine</i> , 2017, 5, 390-390.	1.7	0
117	Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM â€œEl Ãamo IIIâ€• retrospective study. <i>PLoS ONE</i> , 2017, 12, e0184181.	2.5	0
118	Distribution of genomically defined recurrence risk in luminal A and B breast tumors defined by immunohistochemistry: A retrospective study in Spanish population. <i>Annals of Oncology</i> , 2017, 28, v56.	1.2	0
119	Prognostic significance of sentinel node biopsy status in cutaneous melanoma: a 21-years prospective study from a single institution. <i>Clinical and Translational Oncology</i> , 2020, 22, 1611-1618.	2.4	0
120	Â¿Cuando merece la pena realizar una linfadenectomÃa en pacientes con micrometÃstasis de melanoma en ganglio centinela? Un anÃlisis retrospectivo de 20 aÃ±os de experiencia. <i>CirugÃa Y Cirujanos</i> , 2021, 89, 457-460.	0.1	0
121	Abstract 5051: microRNA based classification of non-BRCA1/2 hereditary breast cancer tumors. , 2012, , .		0
122	Family history record and hereditary cancer risk perception after the creation of a heredofamilial cancer unit in a Spanish hospital.. <i>Journal of Clinical Oncology</i> , 2012, 30, e12003-e12003.	1.6	0
123	Abstract P5-15-08: Exercise intervention to run away from breast cancer treatment side effects: An integrative approach. , 2015, , .		0
124	Abstract P1-10-10: An integrative intervention to change breast cancer patients' lifestyle: A medical challenge. A randomize controlled trial. , 2016, , .		0
125	Abstract P4-20-01: Implications of financial modeling in breast cancer clinical research from 1990 to 2010. , 2017, , .		0
126	Highlights of the season 2016â€œ2017 by the Spanish Melanoma Group (GEM). <i>Annals of Translational Medicine</i> , 2017, 5, 391-391.	1.7	0



#	ARTICLE	IF	CITATIONS
127	P162â€¦Lynch syndrome followed up in a hereditary gynaecological cancer unit. , 2019, , .		0
128	Patterns of disease presentation, treatment choices and survival in real world for patients diagnosed with advanced melanoma: A prospective observational study by Spanish Melanoma Group (GEM-1801).. Journal of Clinical Oncology, 2020, 38, e22022-e22022.	1.6	0